» Articles » PMID: 20064603

Oxidative Stress: Biomarkers and Novel Therapeutic Pathways

Overview
Journal Exp Gerontol
Specialty Geriatrics
Date 2010 Jan 13
PMID 20064603
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress significantly impacts multiple cellular pathways that can lead to the initiation and progression of varied disorders throughout the body. It therefore becomes imperative to elucidate the components and function of novel therapeutic strategies against oxidative stress to further clinical diagnosis and care. In particular, both the growth factor and cytokine erythropoietin (EPO) and members of the mammalian forkhead transcription factors of the O class (FoxOs) may offer the greatest promise for new treatment regimens since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion. Furthermore, both EPO and FoxOs function not only as therapeutic targets, but also as biomarkers of disease onset and progression, since their cellular pathways are closely linked and overlap with several unique signal transduction pathways. However, biological outcome with EPO and FoxOs may sometimes be both unexpected and undesirable that can raise caution for these agents and warrant further investigations. Here we present the exciting as well as complicated role EPO and FoxOs possess to uncover the benefits as well as the risks of these agents for cell biology and clinical care in processes that range from stem cell development to uncontrolled cellular proliferation.

Citing Articles

Is age more than a number? Accounting for adult development and aging in the study of psychoneuroimmunology, stress, and health.

Wilson S Compr Psychoneuroendocrinol. 2024; 20:100266.

PMID: 39445313 PMC: 11497474. DOI: 10.1016/j.cpnec.2024.100266.


The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk.

Maiese K Front Immunol. 2023; 14:1273570.

PMID: 38022638 PMC: 10663950. DOI: 10.3389/fimmu.2023.1273570.


Innovative therapeutic strategies for cardiovascular disease.

Maiese K EXCLI J. 2023; 22:690-715.

PMID: 37593239 PMC: 10427777. DOI: 10.17179/excli2023-6306.


Cognitive Impairment in Multiple Sclerosis.

Maiese K Bioengineering (Basel). 2023; 10(7).

PMID: 37508898 PMC: 10376413. DOI: 10.3390/bioengineering10070871.


Anti-Skin Inflammatory and Anti-Oxidative Effects of the Neoflavonoid Latifolin Isolated from in HaCaT and BJ-5ta Cells.

Dong L, Lee H, Liu Z, Lee D Int J Mol Sci. 2023; 24(8).

PMID: 37108534 PMC: 10138365. DOI: 10.3390/ijms24087371.


References
1.
Eliopoulos N, Gagnon R, Francois M, Galipeau J . Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol. 2006; 17(6):1576-84. DOI: 10.1681/ASN.2005101035. View

2.
Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M . High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 45(9):1406-12. DOI: 10.1016/j.jacc.2005.01.043. View

3.
Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, Leotsinidis M, Kyriazopoulou V, Vassilakos P . Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol. 2005; 85(2):79-85. DOI: 10.1007/s00277-005-1102-9. View

4.
Taylor D, MAXWELL M, Luthi-Carter R, Kazantsev A . Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci. 2008; 65(24):4000-18. PMC: 11131895. DOI: 10.1007/s00018-008-8357-y. View

5.
Chong Z, Kang J, Maiese K . Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab. 2003; 23(3):320-30. DOI: 10.1097/01.WCB.0000050061.57184.AE. View